DOCSLIB.ORG

Why Was HIV-1 Able to Cause the AIDS Pandemic?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Why Was HIV-1 Able to Cause the AIDS Pandemic? Why was HIV-1 able to cause the AIDS pandemic? Garland Science, 2005 Frank Kirchhoff Institute of Molecular Virology Ulm University Medical Clinic HIV: structure and genome 10 genes and 10.000 basepairs (humans ~21.000 and 3 billion) HIV: structure and genome 10 genes and 10.000 basepairs (humans ~21.000 and 3 billion) HIV: structure and genome 10 genes and 10.000 basepairs (humans ~21.000 and 3 billion) HIV: why is the virus so successful? Strong Glycosylation, conserved domains are „masked“ and only transiently exposed • Camouflage • Highly variable Envelope trimer • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow • Viral Antagonists Pancera et al., Nature (2014) • Manipulation of host cells HIV: why is the virus so successful? Error rate of RT ~ 1 : 10.000 Generation time 1-2 days • Camouflage Billions of progeny virions • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow • Viral Antagonists • Manipulation of host cells HIV: why is the virus so successful? Error rate of RT ~ 1 : 10.000 Generation time 1-2 days • Camouflage Billions of progeny virions • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow • Viral Antagonists • Manipulation of host cells HIV: why is the virus so successful? • Camouflage Latent infection of long-living cells • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow Stevenson, Nat. Med. 2003 • Viral Antagonists • Manipulation of host cells HIV: why is the virus so successful? Infection of specific • Camouflage body compartments • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow • Viral Antagonists • Manipulation of host cells McArthur et al. Ann Neurol. (2010) HIV: why is the virus so successful? HIV destroys CD4+ helper T-cells • Camouflage • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow • Viral Antagonists • Manipulation of host cells HIV: why is the virus so successful? • Camouflage Direct transfer: Protection against CTLs & Abs • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow • Viral Antagonists • Manipulation of host cells Haller & Fackler, Biol. Chem. (2008) HIV: why is the virus so successful? Cytotoxic T cells come too late • Camouflage (antibodies anyway…) • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow • Viral Antagonists • Manipulation of host cells Haase, Nature (2010) HIV: why is the virus so successful? • Camouflage • Highly variable • Can become invisible • Hide • Immunodeficiency • Cell-Cell Spread • Immune response is too slow •Viral Antagonists • Manipulation of host cells HIV-1: replication cycle Restriction factors: cellular inhibitors of viral replication TRIM5: destabilization of the viral capsid APOBEC3G: Hyper-Mutationen Tetherin: Hemmung der Virusfreisetzung Restriction factors: cellular inhibitors of viral replication TRIM5: destabilization of the viral capsid APOBEC3G: hyper-mutations Tetherin: Hemmung der Virusfreisetzung Restriction factors: cellular inhibitors of viral replication TRIM5: destabilization of the viral capsid APOBEC3G: hyper-mutations Tetherin: inhibition of virus release Humans developed a „natural combination therapy“ TRIM5: destabilization of the viral capsid APOBEC3G: hyper-mutations Tetherin: inhibition of virus release The number of restriction factors is increasing TRIM5, APOBEC3G, tetherin, SamHD1, … SerinC5 HIV-1 infection control SerinC5 Pizzato et al. Nature, in press Göttlinger et al. Nature, in press Restriction factors share some characteristics 1. inducible by interferons 2. interacting with viral components 3. under high positive selection pressure GBP5: affects HIV-1 Env function Restriction factors share some characteristics 1. inducible by interferons 2. interacting with viral components 3. under high positive selection pressure GBP5: affects HIV-1 Env function Key role in macrophages http://interactive-biology.com If there are so many anti-HIV factors: Why do they NOT efficiently control HIV-1? HIV-1: evasion or counteraction of antiviral factors TRIM5: destabilization of the viral capsid resistance APOBEC3G: hyper-mutations Tetherin: inhibition of virus release HIV-1: evasion or counteraction of antiviral factors TRIM5: destabilization of the viral capsid resistance APOBEC3G: hyper-mutations Antagonist: Vif Tetherin: inhibition of virus release HIV-1: evasion or counteraction of antiviral factors TRIM5: destabilization of the viral capsid resistance APOBEC3G: hyper-mutations Antagonist: Vif Tetherin: inhibition of virus release Antagonist: Vpu Nef antagonizes SerinC5 Removal from nef-defective Wild-type the cell surface control control control SerinC5 SerinC5 Nef Pizzato et al., Nature, in press HIV-1 evolved tools to antagonize restriction factors HIV: why is the virus so successful? Vif, Vpu, Vpr & Nef allow the virus to antagonize antiviral factors Kirchhoff, Cell Host & Microbe (2010) If restriction factors are inactive against HIV-1: are they good for anything? Evolutionary arms race Antiviral protein Viral target or “red queen” hypothesis Host adapts Resistance Host adapts Resistance Now, here, you see, it takes all the running you can do, to keep in the same place (Carroll, Lewis, 1998) Antiviral proteins are highly variable and often species-specific Monkey TRIM5 protects cats against FIV FIV resistent (Wongsrikeao et al., Nat. Methods 2011) HIV: origin ~1920 HIV: spread The AIDS pandemic • 35 million people living with HIV • 2.3 million infections per year • about 35 million deaths Eastern Europe & Central Asia Western Europe 1.2 million North America 570 000 980 000 East Asia & Pacific North Africa 1.2 million Caribbean & Middle East South 440 000 550 000 & South-East Asia 6 million Sub-Saharan Latin America Africa Australia 1.5 million 29.4 million & New Zealand 15 000 UNAIDS/WHO 2013 HIV: original hosts - chimpanzees, gorillas & mangabeys Bieniasz & Ho Cell 2008 Some naturally infected monkeys do NOT develop disease HIV/AIDS: origin HIV-1 group N HIV-1 group O Kinshasa: 1959 HIV-1 group P HIV-1 group M HIV: field studies Photos: courtesy of Beatrice Hahn Photos: courtesy of Beatrice Hahn HIV-1: multiple cross-species transmissions Monkeys Greater apes Humans Sauter et al., Cell 2010 HIV-1: multiple cross-species transmissions barriers: APOBEC3G, TRIM5, tetherin,… APOBEC3G, TRIM5, tetherin,… Sauter et al., Cell 2010 Recombination helped SIVs to cross the barrier from monkeys to chimpanzees recombination Generation of a functional Vif Adaptation to apes „inactivated“ human TRIM5 and APOBEC3G APOBEC3G,X TRIM5,X Tetherin 70 million 17 100.000 2 Courtesy Paul Spearman Adaptation to apes „inactivated“ human TRIM5 and APOBEC3G Why did only HIV-1 group M cause a pandemic? 70 million 17 100.000 2 Courtesy Paul Spearman Tetherin: a broad-based inhibitor of virus release MLV SIV HIV HHV-8 XMRV Lassa virus Sauter and Kirchhoff, Curr HIV Res. 2011 Marburg virus Ebola virus VSV JSRV PERV adapted from Murphy, UC, USA Vpu antagonizes tetherin, which blocks virus release and induces CD4 degradation Neil et al., Nature 2008; Van Damme et al., Cell HMi 2008 Arias et al., 2011, Frontiers in Microbiology Courtesy Paul Spearman Tetherin is a barrier to successful zoonotic transmission (Sauter et al., Cell HM 2009, Cell 2010; Retrovirology 2011; PLOS Path. 2012, others) HIV-1 Vpu function M N O P Tetherin + (+) - - CD4 + - + + Sauter et al., Cell (2010) Only HIV-1 M Vpu is “optimally” adapted to humans Effective tetherin antagonism may promote HIV-1 transmission by enhancing genital shedding of virions Effective tetherin antagonist No tetherin antagonist Bieniasz, CROI 2014 Most primate lentiviruses use Nef to antagonize tetherin Jia et al., 2009; Sauter et al., 2009; Zhang et al., 2009 SIVcpz & SIV gor Tetherin CT Perez-Caballero et al., 2009 Nef Human tetherin contains a deletion that renders it resistent to Nef Ancient origin of the protective deletion in human tetherin (Sauter et al., Hum. Mut. 2011) Neanderthal Denisova modern human 1.0 0.5 0.0 mya VERY ancient origin of tetherin and its antiviral activity ~350 million years old nhm.ac.uk tybeemarinescience.org HIV-1 group M switched from Nef to Vpu Sauter et al., Cell HM 2009 SIVcpz & SIV gor HIV-1 M & N Tetherin Tetherin TM CT Nef Vpu HIV-1 group N is still adapting to humans (Sauter et al., PLOS Path. 2012) The most recently transmitted HIV-1 N strain is fully active against human tetherin HIV-1 O restored anti-tetherin activity of Nef in humans (Kluge, Mack et al., Cell Host & Microbe 2014) Why did only HIV-1 group M cause the AIDS pandemic? It evolved Vpu as highly effective tetherin antagonist Why does HIV-1 cause chronic immune activation and AIDS? Differences between HIV-1 and SIVsmm or SIVagm: Presence of vpu and differences in Nef function Differences between HIV-1 and SIVsmm or SIVagm: Presence of vpu and differences in Nef function Nef is critical for efficient viral replication in vivo (Kestler et al., Cell 1991; Deacon et al., Science 1995; Kirchhoff et al., New Engl J Med. 1995) nef+: sAIDS nef: No disease Nef: structure and function Nef: structure and function CD4 cell membrane myristoylated Nef Uptake globular core AP2 cellular receptors endosome 2 flexible loops AP Uptake
Load more

Recommended publications
  • A Truncated Nef Peptide from Sivcpz Inhibits the Production of HIV-1 Infectious Progeny
    viruses Article A Truncated Nef Peptide from SIVcpz Inhibits the Production of HIV-1 Infectious Progeny Marcela Sabino Cunha 1,†, Thatiane Lima Sampaio 1,†, B. Matija Peterlin 2 and Luciana Jesus da Costa 1,* 1 Departamento de Virologia—Instituto de Microbiologia, Universidade Federal do Rio de Janeiro, Av. Carlos Chagas Filho 373—CCS—Bloco I, Rio de Janeiro 21941-902, Brazil; [email protected] (M.S.C.); [email protected] (T.L.S.) 2 Departments of Medicine, Microbiology and Immunology, University of California, San Francisco, 533 Parnassus Avenue, San Francisco, CA 94143, USA; [email protected] * Correspondence: [email protected]; Tel.: +55-21-2560-8344 (ext. 117); Fax: +55-21-2560-8344 † These authors contributed equally to this work. Academic Editor: Andrew Mehle Received: 29 February 2016; Accepted: 14 June 2016; Published: 7 July 2016 Abstract: Nef proteins from all primate Lentiviruses, including the simian immunodeficiency virus of chimpanzees (SIVcpz), increase viral progeny infectivity. However, the function of Nef involved with the increase in viral infectivity is still not completely understood. Nonetheless, until now, studies investigating the functions of Nef from SIVcpz have been conducted in the context of the HIV-1 proviruses. In an attempt to investigate the role played by Nef during the replication cycle of an SIVcpz, a Nef-defective derivative was obtained from the SIVcpzWTGab2 clone by introducing a frame shift mutation at a unique restriction site within the nef sequence. This nef -deleted clone expresses an N-terminal 74-amino acid truncated peptide of Nef and was named SIVcpz-tNef. We found that the SIVcpz-tNef does not behave as a classic nef -deleted HIV-1 or simian immunodeficiency virus of macaques SIVmac.
    [Show full text]
  • Week 6 AIDS Part
    Age of AIDS, Part Two. Scientific Breakthroughs National Institutes of Health, Bethesda, Maryland. >>NARRATOR: At the NIH, research scientists were trying to identify the mysterious agent that was causing the epidemic. >>DR. ANTHONY FAUCI: It was a period of evolving mystery. You couldn't see it, you look in the cells, you couldn't grow it, at least initially, and most everybody thought it was virus. >>NARRATOR: And many people thought that this man at the NIH, Dr. Robert Gallow, had a head start in the race to identify the virus. >>GEORGE SHAW, M.D. Ph.D.: I arrived in Bob Gallow's lab in 1983 and it was time of extraordinary excitement. >>NARRATOR: Four years earlier, Dr. Gallow had achieved a scientific breakthrough when he isolated a special virus, a retrovirus which caused leukemia. >>They were called HTLV 1 for human T-cell Leukemia Virus Type 1 and HTLV Type 2. Those viruses were actually prime candidates for the cause of AIDS. >>NARRATOR: Dr. Gallow and his team, convinced the AIDS virus was related to the HTLV, began probing the blood from an AIDS patient, using the same techniques he had used to discover the leukemia virus. >>DR. GALLOW: We were looking for HTLV-relatedness. We were looking for the AIDS virus to be related to the leukemia virus, a retrovirus, same family, but different. >>NARRATOR: But when Gallow cultured T-cells blood from the AIDS patients, he could find no markers of the HTLV. For Gallow, the idea that the AIDS virus could be anything except a variation of the HTLV seemed unthinkable.
    [Show full text]
  • CURRICULUM VITAE, July 2021
    CURRICULUM VITAE, July 2021 MARTIN NICHOLAS MULLER Department of Anthropology University of New Mexico MSC 01 1040 Albuquerque, NM 87131-0001 USA e-mail: [email protected] websites: http://mnmuller.wordpress.com/ http://kibalechimpanzees.wordpress.com/ Education 2002 University of Southern California, Ph.D. in Anthropology 1994 University of Southern California, B.A. in Anthropology (Summa Cum Laude) Research Interests Behavioral ecology, Reproductive ecology, Endocrinology, Primate models in human evolution Academic Positions 2021- University of New Mexico, Department of Anthropology Professor 2011- 2021 University of New Mexico, Department of Anthropology Associate Professor 2007-2011 University of New Mexico, Department of Anthropology Assistant Professor 2004-2007 Boston University, Department of Anthropology Assistant Professor 2004 Harvard University, Department of Anthropology Postdoctoral Fellow 2003 University of Michigan, Department of Anthropology Visiting Research Investigator 1999-2002 Harvard University, Department of Anthropology Postdoctoral Fellow Professional Service 2018- Editorial Board Member, American Journal of Physical Anthropology 2013- Scientific Executive Committee, The Leakey Foundation 2010- Consulting Editor, Human Nature Awards and Fellowships 1998 Haynes Foundation Dissertation Fellowship 1994 University of Southern California, All-University Pre-Doctoral Merit Fellowship 1994 Phi Beta Kappa 1990 University of Southern California, Dean’s Scholarship Active Research Grants 2019 National Science Foundation. The evolutionary origins of leadership in chimpanzees: from individual minds to collective action. PIs: Alexandra Rosati (UM), Zarin Machanda (Tufts), Melissa Emery Thompson (UNM), and Martin Muller (UNM) Completed Research Grants 2015 National Institutes of Aging (PI: Melissa Emery Thompson). Biodemography of Aging in Wild Chimpanzees. (5-year grant) Co-Investigator. 2014 National Science Foundation. Developmental integration and the ecology of life histories in phylogenetic perspective.
    [Show full text]
  • The AIDS Epidemic and Its Spread in the for Additional Reading United States and the World
    © Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC NOT FOR SALE OR DISTRIBUTION NOT FOR SALE OR DISTRIBUTION CHAPTER© Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC NOT FOR SALE The OR DISTRIBUTION AIDS NOT FOR SALE OR DISTRIBUTION 1 Epidemic © Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC NOT FOR SALE OR DISTRIBUTION NOT FOR SALE OR DISTRIBUTION LOOKING AHEAD © Jones & Bartlett Learning, LLC © Jones & Bartlett Learning, LLC CHAPTER NOT FOR SALEJune 5,OR 2011 DISTRIBUTION marked 30 years since the Centers forNOT Disease FOR Control SALE and ORPrevention DISTRIBUTION (CDC) reported the fi rst cases of AIDS in the United States in its weekly Morbidity OUTLINE and Mortality Weekly Report (MMWR). The chronological milestone provides an opportunity to refl ect upon the status of HIV/AIDS in the world today. Since these Looking Ahead fi rst fi ve cases were reported, nearly 600,000 people have died in the United States as a result of HIV/AIDS.© Jones Worldwide, & Bartlett 30 million Learning, people LLChave died of HIV-related © JonesIntroduction & Bartlett Learning, LLC causes. There is stillNOT no vaccineFOR SALE available OR to DISTRIBUTIONprevent this viral disease. However, thereNOT TheFOR Early SALE Years OR DISTRIBUTION remains hope that this viral disease will be conquered one day. Development of anti- The First Observations virals to treat patients, along with improved HIV diagnosis methods, have increased The Breakthrough the life expectancy of U.S. patients after HIV diagnosis from 10.5 to 22.5 years. Another AIDS Virus This opening chapter introduces acquired immune deficiency syndrome (AIDS) A Pandemic by© exploringJones & the Bartlett development Learning, of its epidemic LLC in the United States and© Jonesthe world & BartlettOrigin Learning, of the AIDS LLC Epidemic andNOT by FORdescribing SALE the ORresearch DISTRIBUTION to uncover its cause.
    [Show full text]
  • New Claims from Paul Sharp - but Has the Source of HIV-1 Really Been Located?
    New Claims from Paul Sharp - But Has the Source of HIV-1 Really Been Located? Introduction February 2006. In recent days there has been much press coverage about new claims by American, British and Belgian scientists that they have discovered the geographical source of AIDS. These researchers have apparently detected simian immunodeficiency viruses (SIVs) that are closely related to the AIDS pandemic virus, HIV-1, in the stools of wild chimpanzees living in the very south-eastern corner of Cameroon, in western Africa. Much of this new information is important and valuable. However, much of the accompanying analysis is exaggerated, and not for the first time seems to be driven by an underlying desire on the part of the authors to bolster the bushmeat theory of origin of AIDS, which proposes that humans first got infected through the butchery and consumption of chimpanzee bushmeat. In fact, as I shall demonstrate, their claims of having established the source of HIV-1 and AIDS are far from convincing. Furthermore, their new findings are as consistent with the oral polio vaccine (OPV) theory of origin as they are with the bushmeat theory. [See note at end of this section for explanation of OPV theory.] The new information about the Cameroonian chimps was released in February 2006 at the 13th Conference on Retroviruses and Opportunistic Infections in Denver, Colorado, where important speeches were made by Brandon Keele, from the lab of microbiologist Beatrice Hahn at the University of Alabama in Birmingham (US); by Fran van Heuverswyn, from Martine Peeters' lab in Montpellier, France; and by Hahn's long-time collaborator, the geneticist Paul Sharp, who is based at the University of Nottingham, UK.
    [Show full text]
  • Comparative Genomics of Ape Plasmodium Parasites Reveals Key Evolutionary Events Leading to Human Malaria
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2016 Comparative Genomics of Ape Plasmodium Parasites Reveals Key Evolutionary Events Leading to Human Malaria Sesh Alexander Sundararaman University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Evolution Commons, Genetics Commons, and the Microbiology Commons Recommended Citation Sundararaman, Sesh Alexander, "Comparative Genomics of Ape Plasmodium Parasites Reveals Key Evolutionary Events Leading to Human Malaria" (2016). Publicly Accessible Penn Dissertations. 2046. https://repository.upenn.edu/edissertations/2046 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2046 For more information, please contact [email protected]. Comparative Genomics of Ape Plasmodium Parasites Reveals Key Evolutionary Events Leading to Human Malaria Abstract African great apes are infected with at least six species of P. falciparum-like parasites, including the ancestor of P. falciparum. Comparative studies of these parasites and P. falciparum (collectively termed the Laverania subgenus) will provide insight into the evolutionary origins of P. falciparum and identify genetic features that influence host tropism. Here we show that ape Laverania parasites do not serve as a recurrent source of human malaria and use novel enrichment techniques to derive near full-length genomes of close and distant relatives of P. falciparum. Using a combination of single template amplification and deep sequencing, we observe no evidence of ape Laverania infections in forest dwelling humans in Cameroon. This result supports previous findings that ape Laverania parasites are host specific and have successfully colonized humans only once. To understand the determinants of host specificity and identify genetic characteristics unique to P.
    [Show full text]
  • Stephen Hahn Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993
    Stephen Hahn Commissioner Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Dear Dr. Hahn: We are experts in virology, epidemiology, vaccinology, infectious disease, clinical care and public health. A vaccine(s) is needed to curtail the COVID-19 pandemic. We are committed to promoting the broad uptake of safe and effective COVID-19 vaccines. The need is urgent but all vaccines must be rigorously studied to determine whether their benefits exceed their risks. For this reason, we urge that COVID-19 vaccines are made widely available only after the Food and Drug Administration (FDA) has been able to evaluate safety and efficacy data from completed Phase 3 clinical trials. The FDA’s review must be as thorough as has been the case for previous vaccine candidates. As transparency will be critical for fostering public confidence and maximizing vaccine use, the open meetings of the FDA’s Vaccines and Related Biologics Product Approval (VRBPAC) Committee must be an essential part of the authorization and approval processes. Several COVID-19 vaccine candidates are now in Phase 3 trials. We hope one or more of them will soon prove to be both safe and effective. The decisions to fund and produce many millions of doses ahead of the trial results should save many months in providing approved vaccines to the American public. In short, productive collaborations between scientists, the pharmaceutical industry and the federal government may bring us to a remarkable and historic achievement – the creation of a vaccine within a year after this pandemic virus was first identified.
    [Show full text]
  • Within-Host Evolution of Hiv-1: Novel Pathways of Virus Escape from Cellular and Humoral Immunity
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2016 Within-Host Evolution Of Hiv-1: Novel Pathways Of Virus Escape From Cellular And Humoral Immunity Edward Kreider University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Microbiology Commons Recommended Citation Kreider, Edward, "Within-Host Evolution Of Hiv-1: Novel Pathways Of Virus Escape From Cellular And Humoral Immunity" (2016). Publicly Accessible Penn Dissertations. 2406. https://repository.upenn.edu/edissertations/2406 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2406 For more information, please contact [email protected]. Within-Host Evolution Of Hiv-1: Novel Pathways Of Virus Escape From Cellular And Humoral Immunity Abstract Longitudinal HIV-1 single genome sequencing (SGS), which permits unambiguous genetic characterization of circulating viral strains without introduction of PCR error, can be used to identify sites in the viral genome that are under selective pressure. Following transmission, the earliest sites under positive selection often fall in cytotoxic T lymphocyte (CTL) epitopes. During escape from CTL immune pressure, viral sequences typically exhibit nonsynonymous mutations within the span of the cognate T cell epitope. I applied SGS to study sequence evolution in the HIV-1 5’ leader sequence, which is thought to be translationally silent. I observed mutational patterns consistent with CTL escape and demonstrated that the HIV-1 5’ leader expresses T cell antigens from non-canonical one-off AUG codons (e.g. CUG). While these non-canonical start codons can be mutated during CTL escape, a reverse transcriptase overextension error periodically restores a one-off AUG within the 5’ leader.
    [Show full text]
  • Molecularbiologyof Humant-Lymphotropicretroviruses
    [CANCER RESEARCH (SUPPL.) 45, 45395-45445, September1985] MolecularBiologyof HumanT-LymphotropicRetroviruses Flossie Wong-Staal, Lee Ratner, George Shaw, Beatrice Hahn, Mary Harper, Genoveffa Franchini,and Robert Gallo LaboratoryofTumorCellBiology,NationalCancerInstitute,Bethesda,Maryland20205 Abstract 7),a recentlyrecognizeddiseasecharacterizedbyopportunistic infectionsasa resultofsevereimmunosuppressionandOKT4 Thegenericnamefora familyofhumanT-Iymphotropicretro helperT-celldepletion(8).Consistentwithdifferencesintheirin virusesisHTLV.Two of thethreemembersinthisfamilyhave vivodiseasespectrums,HTLV-Iand HTLV-IItransformT-lym beenlinkedetiologicallyto humandiseases:HTLV-lwith adult phocytesin vitro,whileHTLV-lIlis highlycytopathicandhasno T-celIleukemiaandHTLV-Illwiththeacquiredimmunodeficiencyapparenttransformingactivity.However,allthreevirusgroups syndrome.InadditiontotheirT-celltropismanda numberof shareat leastthesecommonproperties:tropismforT-lympho othercommonbiologicalandbiochemicalproperties,themost cytes;somedegreeof cytopathyfor the infectedcells;induction uniquecommonfeaturesof thesevirusesfroma molecular of multinudeatedgiantcellsandformationofsyncytia;aMg@@ biologicalpointofviewarethepresenceofthex-Iorgenetowards preferringreversetranscnptaseofhighmolecularweight;a small the 3' end of the genomeand the phenomenonofa virus majorcoreprotein(p24);commonepitopesofgagandenvelope inducedtrans-actingfactorin activationof transcriptioninitiated proteins;anda likelyAfricanorigin. in the virallongterminalrepeat.Thesefeaturesmaynot onlybe
    [Show full text]
  • HIV/AIDS Research at the NCI:A Record of Sustained Excellence
    HIV/AIDS Research at the NCI: A Record of Sustained Excellence National Cancer Institute Institute Cancer National U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health HIV/AIDS Research at the National Cancer Institute: A Record of Sustained Excellence Letter from the Director of the CCR ............................................................................................................1 The Early NCI Retrovirus Experience ...........................................................................................................2 A New Virus Revealed ......................................................................................................................2 Risk Factors ........................................................................................................................................4 A Tale of Two Diseases ...............................................................................................................................5 Treating the Infection .........................................................................................................................5 Treating the Cancers .........................................................................................................................6 HIV and the Immune System: How They Interact........................................................................................8 Susceptibility to Infection, AIDS, and Related Diseases ..........................................................................10
    [Show full text]
  • Dr Robert Gallo Interview 02 November 4 1994 Interview with Dr
    Dr Robert Gallo Interview 02 November 4 1994 Interview with Dr. Robert Gallo This is the second oral history interview with Dr. Robert Gallo of the National Cancer Institute about the history of AIDS at the National Institutes of Health. The date is 4 November 1994. The interviewers are Dr. Victoria A. Harden, Director, NIH Historical Office, and Dennis Rodrigues, program analyst, NIH Historical Office. Harden: Dr. Gallo, when we ended the first interview, we had set the stage for the discussion of AIDS. We had talked about when [Dr. James] Jim Curran [of the Centers for Disease Control and Prevention] came to the NIH [National Institutes of Health] and was prodding you to go into AIDS research. Much of your early work has been detailed in many different places–in your book and in a variety of other publications–so what we would like to do in this interview is to have a few points amplified, not to attempt to recount all the facts. One of the key questions that has come up over and over again is how, when a new disease appears, can it be demonstrated that a particular agent is the cause of it? Chronologically, the French isolated their virus, LAV, in 1983, but they did not demonstrate conclusively that there was a causal link between their virus and AIDS. You waited until May 1984, and then published four papers in Science to do this. In fact, you wrote to [Dr.] Jean-Claude Chermann noting that you wanted to wait to publish in order to obtain a certain number of papers to establish the etiology.
    [Show full text]
  • CXCR6-Mediated Simian Immunodeficiency Virus
    CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections Katherine Wetzel, Yanjie Yi, Sarah Elliott, Dino Romero, Béatrice Jacquelin, Beatrice Hahn, Michaela Muller-Trutwin, Cristian Apetrei, Ivona Pandrea, Ronald Collman To cite this version: Katherine Wetzel, Yanjie Yi, Sarah Elliott, Dino Romero, Béatrice Jacquelin, et al.. CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections. Journal of Virology, American Society for Microbiology, 2017, 91 (4), pp.e01626-16. 10.1128/jvi.01626-16. pasteur- 01960612 HAL Id: pasteur-01960612 https://hal-pasteur.archives-ouvertes.fr/pasteur-01960612 Submitted on 19 Dec 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. PATHOGENESIS AND IMMUNITY crossm CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections Katherine S. Wetzel,a Yanjie Yi,a Sarah T. C. Elliott,a Dino Romero,a Beatrice Jacquelin,b Beatrice H. Hahn,a Michaela Muller-Trutwin,b Cristian Apetrei,c Ivona Pandrea,c Ronald G.
    [Show full text]